These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20634701)

  • 1. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
    Hu Z; Kuritzkes DR
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
    Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
    Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
    Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
    J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
    Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
    Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.
    Delelis O; Malet I; Na L; Tchertanov L; Calvez V; Marcelin AG; Subra F; Deprez E; Mouscadet JF
    Nucleic Acids Res; 2009 Mar; 37(4):1193-201. PubMed ID: 19129221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
    Nguyen HL; Charpentier C; Nguyen N; de Truchis P; Molina JM; Ruxrungtham K; Delaugerre C
    HIV Med; 2013 Feb; 14(2):85-91. PubMed ID: 22994529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
    Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
    J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.
    Quercia R; Dam E; Perez-Bercoff D; Clavel F
    J Virol; 2009 Oct; 83(19):10245-9. PubMed ID: 19605484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
    Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
    Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
    J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.
    Fransen S; Gupta S; Frantzell A; Petropoulos CJ; Huang W
    J Virol; 2012 Jul; 86(13):7249-55. PubMed ID: 22553340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
    Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
    Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
    Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
    Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.
    Garrido C; de Mendoza C; Alvarez E; García F; Morello J; Garcia S; Ribera E; Rodríguez-Novoa S; Gutierrez F; Soriano V;
    AIDS Res Hum Retroviruses; 2012 Feb; 28(2):156-64. PubMed ID: 21457126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.